Table 1.
Clinical characteristics of patients in groups C, D1, and D2
|
|
Group C (n = 40)
|
Group D1 (n = 40)
|
Group D2 (n = 40)
|
P
value
|
| Sex, F/M | 11/29 | 12/28 | 10/30 | 0.8820 |
| Age, yr | 52.73 ± 10.68 | 52.33 ± 7.99 | 51.73 ± 8.58 | 0.886 |
| BMI, kg/m2 | 25.58 ± 2.70 | 26.15 ± 1.70 | 25.95 ± 2.04 | 0.505 |
| Hypertension, Yes/No | 11/29 | 12/28 | 15/25 | 0.606 |
| DM, Yes/No | 6/34 | 5/35 | 5/35 | 0.930 |
| ASA, I/II | 10/30 | 7/33 | 6/34 | 0.497 |
| Duration of anaesthesia, min | 148.95 ± 49.54 | 145.90 ± 47.24 | 144.60 ± 50.24 | 0.920 |
| Duration of surgery, min | 128.48 ± 46.83 | 130.90 ± 47.13 | 127.33 ± 50.18 | 0.944 |
| Dosage of sufentanil during surgery, μg | 32.58 ± 7.20 | 31.63 ± 3.28 | 32.75 ± 3.91 | 0.570 |
| Dosage of sufentanil after surgery (8 h), mL | 16.35 ± 0.51 | 16.15 ± 0.43 | 16.29 ± 0.53 | 0.180 |
| Dosage of sufentanil after surgery (24 h), mL | 48.41 ± 0.59 | 48.26 ± 0.76 | 48.30 ± 0.60 | 0.566 |
| Postoperative stay in hospital, d | 8.60 ± 1.72 | 8.38 ± 1.35 | 8.43 ± 1.68 | 0.803 |
Variables are presented as the mean ± SD or number of patients. None showed any statistical significance (P > 0.05). ASA: American Society of Anesthesiologists, BMI: Body mass index, DM: Diabetes mellitus.